Unprecedented New Clinical Trial Set Using MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision Making and Patient Outcomes
TORONTO and SALT LAKE CITY, Utah, Nov. 10, 2022 /PRNewswire/ -- MolecuLight Inc., a leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that its technology will be featured in over 10 clinical and poster presentations at the link, titled Technology in Wound Care. The national conference, to be held November 10-12, 2022, in Salt Lake City, Utah, will focus on the utility of new technologies in improving wound care and clinical outcomes. It will include a combination of nine clinical posters, a clinical talk, and a hands-on workshop with MolecuLight devices.
"The rise of technological innovation in wound care is transforming the way we work. At the Technology in Wound Care conference, we bring together the latest and most impactful technologies to share evidence and clinical perspectives on how they improve wound care decisions. treatment and patient outcomes," said Alisha Oropallo, MD, FACS, FSVS, FAPWCA, FABWMS, AAWC conference co-chair and medical director of the Comprehensive Center for Hyperbaric and Wound Healing, Northwell Health, New York. "MolecuLight has extensively validated its point-of-care imaging technology for the detection of wound regions harboring bacterial loads of clinical concern and for digital wound measurement. They are market leaders and have set the standard of validation testing for wound imaging technologies. As such, it is fitting that the MolecuLight be featured in so many clinical presentations, demonstrations and posters, including over 1,800 new wound tests being shown at this meeting. This innovative technology has become a standard of care in my practice, where it serves as an essential tool to inform and improve our clinical decision making."
New MolecuLight tests to be presented at AAWC 2022 include:
Specific clinical presentations and posters featuring the MolecuLight i:X and DX from AAWC 2022 are as follows:
a) CLINICAL PRESENTATIONS
b) CLINICAL POSTERS
In addition to clinical posters and presentations at AAWC Annual Conference 2022, MolecuLight i:X® and DX™ imaging devices will be featured at Integrating Technology Into Wound Care hands-on workshop on Thursday, November 10, 2022. They will also be available for demonstration at the booth
MolecuLight i:X and DX are the only imaging devices for real-time detection of elevated bacterial load in wounds that have FDA clearance, CE and Health Canada clearance. With clinical evidence including more than link, they are used by leading wound care centers around the world.
About MolecuLight Inc.
MolecuLight Inc. is a privately held medical imaging company that has developed and commercializes its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercially launched devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provides portable point-of-care imaging devices for the global wound care market for liaison and for digital wound measurement. MolecuLight procedures performed in the United States may benefit from an available reimbursement pathway that includes two CPT® codes for physician work to perform "fluorescence imaging to determine the presence, location, and load of bacteria" and facility payment for hospital outpatient department (HOPD) and ambulatory surgical center (ASC) through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with relevant unmet needs globally, such as food safety, consumer cosmetics and other key industrial markets.
www.moleculight.com
CONTACTO: Rob Sandler, director de marketing, MolecuLight Inc., T. 1.647.362.4684, rsandler@moleculight.com
Photo - link
View original content: enlace
